APOE2 Protects Neurons by Reducing DNA Damage
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Buck Institute researchers found that APOE2 neurons accumulate significantly less DNA damage than neurons carrying APOE3 or APOE4, with direct measurements of DNA strand breaks confirming the pattern across two neuron types.
- The study, published in Aging Cell, used human iPSCs engineered to differ only at the APOE locus — converted into GABAergic and glutamatergic neurons — alongside hippocampal tissue from older mice carrying human APOE2, APOE3, or APOE4.
- APOE2 GABAergic neurons strongly activated DNA repair and damage-response pathways in bulk and single-cell RNA sequencing, while APOE4 neurons displayed gene activity patterns associated with Alzheimer's disease.
- When exposed to radiation or the chemotherapy drug doxorubicin, APOE2 excitatory neurons showed lower senescence markers (p16, CRYAB), smaller nucleoli, and better-preserved nuclear architecture than the other variants.
- Adding recombinant APOE2 protein to APOE4 neurons reduced DNA damage signaling after radiation exposure, suggesting the protective effect may be transferable rather than limited to people born with the variant.
- Older APOE2 knock-in mice had smaller nucleoli, higher Lamin A/C levels, and better-preserved heterochromatin in the hippocampus than mice carrying APOE3 or APOE4 — mirroring the human neuron findings.
- Senior author Lisa M. Ellerby says the findings connect a major longevity gene to DNA repair and senescence — two hallmarks of aging — opening therapeutic directions beyond the field's traditional focus on lipid handling and amyloid-beta.
Why it matters: This reframes the APOE4 gene — the strongest known genetic risk factor for late-onset Alzheimer's — as a potentially modifiable target rather than an inherited sentence. The finding that recombinant APOE2 protein can reduce DNA damage signaling in APOE4 neurons shifts the therapeutic approach from inherited risk toward treatable biology, and the Buck team plans to explore APOE2-mimetic compounds and targeted DNA repair treatments for APOE4 carriers.
